|
Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) |
|
ID |
4625290 |
Author(s) |
Kolaczynska, Karolina E; Liechti, Matthias E; Duthaler, Urs |
Author(s) at UniBasel |
Liechti, Matthias Emanuel
|
Year |
2021 |
Title |
Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma. |
Journal |
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences |
Volume |
1164 |
Pages / Article-Number |
122486 |
Keywords |
Drug screening; Glucuronidation; Metabolism; Pharmacokinetics; Psychedelic drugs |
Mesh terms |
Administration, Oral; Chromatography, Liquid, methods; Hallucinogens, blood, chemistry, pharmacokinetics; Humans; Hydroxyindoleacetic Acid, analogs & derivatives, blood, chemistry, pharmacokinetics; Linear Models; Psilocybin, administration & dosage, analogs & derivatives, blood, chemistry, pharmacokinetics; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry, methods |
Abstract |
Psilocin is the active metabolite of psilocybin, a serotonergic psychedelic substance. It is used recreationally and investigated in substance-assisted psychotherapy. The pharmacokinetic properties of psilocin are only partially characterized. Therefore, we developed and validated a rapid LC-MS/MS method to quantify psilocin and its metabolite 4-hydroxyindole-3-acetic acid (4-HIAA) in human plasma. Plasma samples were processed by protein precipitation using methanol. The injected sample was mixed with water in front of a C; 18; analytical column to increase retention of the analytes. Psilocin and 4-HIAA were detected by multiple reaction monitoring (MRM) in positive and negative electrospray ionisation mode, respectively. An inter-assay accuracy of 100-109% and precision of ≤8.7% was recorded over three validation runs. The recovery was near to complete (≥94.7%) and importantly, consistent over different concentration levels and plasma batches (CV%: ≤4.1%). The plasma matrix caused negligible ion suppression and endogenous interferences could be separated from the analytes. Psilocin and 4-HIAA plasma samples could be thawed and re-frozen for three cycles, kept at room temperature for 8 h or 1 month at -20 °C without showing degradation (≤10%). The linear range (R ≥ 0.998) of the method covered plasma concentrations observed in humans following a common therapeutic oral dose of 25 mg psilocybin and was therefore able to assess the pharmacokinetics of psilocin and 4-HIAA. The LC-MS/MS method was convenient and reliable for measuring psilocin and 4-HIAA in plasma and will facilitate the clinical development of psilocybin. |
ISSN/ISBN |
1873-376X |
Full Text on edoc |
|
Digital Object Identifier DOI |
10.1016/j.jchromb.2020.122486 |
PubMed ID |
http://www.ncbi.nlm.nih.gov/pubmed/33485158 |
|
|
|
MCSS v5.8 PRO. 0.348 sec, queries - 0.000 sec
©Universität Basel | Impressum
| |
02/05/2024
Research Database / FORSCHUNGSDATENBANK
|